NCT04187625

Cell-based Therapy for the Treatment of Kidney Disease

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.

Detailed description

This is an interventional study involving patients that have a diagnosis of chronic kidney disease. Patients will have at least stage 3 chronic kidney disease stage or greater. Kidney-derived endothelial progenitor cells will have been obtained using associated protocols that are currently approved by the Partners Human Research Committee.

Conditions

• Kidney Diseases

Interventions

Type	Name	Description
BIOLOGICAL	endothelial progenitor cell	Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.

Timeline

• Start date: 2023-01-01
• Primary completion: 2024-01-01
• Completion: 2025-05-01
• First posted: 2019-12-05
• Last updated: 2022-07-26